Sun Pharmaceutical Industries(SUN.NS) said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's (NOVOb.CO) Prandin diabetes drug.
Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo.
Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug.
A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.
(Reporting by Sumeet Chatterjee in MUMBAI; Editing by Supriya Kurane)
Fed's Yellen offers dose of uncertainty to markets hungry for a clue
JACKSON HOLE, Wyoming To markets hungry for direction from the U.S. Federal Reserve, Fed Chair Janet Yellen offered a sobering dose of uncertainty for monetary policy and the global economy on Friday, suggesting interest rates could rise faster than expected in coming months or just as easily crater back to zero.
Yellen's case for rate hike boosts dollar; stocks surrender gains
NEW YORK U.S. equities gave up early gains on Friday, hurt by a surging U.S. dollar after Federal Reserve Chair Janet Yellen said that the case for raising U.S. interest rates has strengthened in recent months.
Castrol India says not aware of any stake sale by BP unit
MUMBAI Castrol India Ltd said on Friday it was not aware of any stake sale in the company by Castrol Ltd, a unit of oil major BP Plc, and said recent news reports that such a transaction would take place were based on market speculation.